BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

I Peace and Vita Therapeutics to develop iPS cells for transplantation therapy

July 10, 2025 | News

With an initial focus on FSHD (Facioscapulohumeral Muscular Dystrophy) using universal iPS cells



Leading GMP cell CDMO I Peace, Inc., specialising in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, has agreed with Vita Therapeutics (Vita) to jointly develop universal iPS cells that will be used for cell transplantation therapy.

GMP-grade iPS cells will be modified with proprietary, licensed gene editing technology to make a base platform hypoimmune line where Class I and II HLA genes that determine rejection have been depleted. These hypoimmune lines can be further customised in I Peace cGMP facilities.

I Peace will provide its GMP iPS cell-related technology to generate the master cell bank (MCB) for the parent line and the modified subclones, while Vita will provide the technology necessary for gene editing and developing iPSC-derived universal cells. The manufactured MCB through this collaboration will be registered in the FDA Drug Master File (DMF).

I Peace will retain rights to supply MCB's of normal and gene-edited cells and to supply differentiated products generated from these lines for cell therapy purposes in all other areas.